Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies
about
Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC)EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.Specific organ metastases and survival in metastatic non-small-cell lung cancer.Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastasesBone-targeted agents in the treatment of lung cancer.Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene TestingHigh Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.First-line treatment of advanced ALK-positive non-small-cell lung cancer.Genetic susceptibility variants for lung cancer: replication study and assessment as expression quantitative trait loci.Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cellsAnti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.Rhesus CE expression on patient red blood cells is an independent prognostic factor for adenocarcinoma of the lung.
P2860
Q34271752-8A5F6F82-6E41-44C8-9793-711C10902B51Q34346624-677CBCCB-6C4F-4311-A623-8EB63662D1D1Q34607284-86F1A092-08A5-4A39-BBA9-FEEEE9A26885Q34886787-C82A23CC-0289-4219-8962-A9E6ABB550DEQ35780792-ACD65BDB-E187-47DD-812F-D11DCE434C77Q35979104-ECB12DC0-FEF2-46FB-ABF8-408F0E558506Q36162776-CBEE6E5E-7D53-4931-A849-BFFA5A6D7B81Q37566842-E73EE777-AEB5-471D-B425-21F504CB7C01Q37633874-61D98E5E-DFA1-4DFF-9A89-942174AC9B63Q37638795-EBEAA44D-5EDB-4C41-88E5-A51B2B41EB8EQ48363650-7A0921E7-ABC9-4E25-BCFE-089344F2D85CQ54301102-237EB757-E495-499C-B282-555F62914447
P2860
Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Determinants of survival in ad ...... the era of targeted therapies
@en
Determinants of survival in ad ...... the era of targeted therapies.
@nl
type
label
Determinants of survival in ad ...... the era of targeted therapies
@en
Determinants of survival in ad ...... the era of targeted therapies.
@nl
prefLabel
Determinants of survival in ad ...... the era of targeted therapies
@en
Determinants of survival in ad ...... the era of targeted therapies.
@nl
P2093
P2860
P1433
P1476
Determinants of survival in ad ...... the era of targeted therapies
@en
P2093
Anil Vachani
Charu Aggarwal
Christopher D Watt
Corey Langer
Joshua Bauml
Rosemarie Mick
Tracey Evans
P2860
P304
P356
10.1016/J.CLLC.2013.05.002
P407
P577
2013-07-01T00:00:00Z